EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.
复制标题

DOI:
10.1371/journal.pone.0012265
复制
发表时间:
2010-08-31
期刊:
影响因子:
3.7
通讯作者:
Mourah S
Mourah S
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Bougatef F;Menashi S;Khayati F;Naïmi B;Porcher R;Podgorniak MP;Millot G;Janin A;Calvo F;Lebbé C;Mourah S

文献摘要

参考文献

被引文献

相似文献

EMMPRIN在黑色素瘤组织中的表达被报道为预后不良的预测因子。在这里,我们证明,EMMPRIN上调VEGF受体-2(VEGFR-2)在两个不同的原发性黑色素瘤细胞系,从而增加这些细胞的迁移和增殖,同时抑制其凋亡。siRNA抑制VEGFR-2表达可消除这些EMMPRIN效应。EMMPRIN对VEGFR-2的调节是通过HIF-2α的过度表达及其易位至细胞核与HIF-1β形成异源二聚体介导的。这些结果得到了EMMPRIN与VEGFR-2在人黑素瘤组织中的表达以及HIF-2α在细胞核中定位程度之间的体内相关性的支持。他们证明了EMMPRIN通过HIF-2α/VEGFR-2介导的机制促进肿瘤进展的新机制,在黑色素瘤细胞恶性肿瘤中具有自分泌作用。因此,在癌症中抑制EMMPRIN可以同时靶向VEGFR-2/VEGF系统和基质降解蛋白酶以阻断肿瘤细胞生长和侵袭。
EMMPRIN's expression in melanoma tissue was reported to be predictive of poor prognosis. Here we demonstrate that EMMPRIN up-regulated VEGF receptor-2 (VEGFR-2) in two different primary melanoma cell lines and consequently increased migration and proliferation of these cells while inhibiting their apoptosis. SiRNA inhibition of VEGFR-2 expression abrogated these EMMPRIN effects. EMMPRIN regulation of VEGFR-2 was mediated through the over-expression of HIF-2α and its translocation to the nucleus where it forms heterodimers with HIF-1β. These results were supported by an in vivo correlation between the expression of EMMPRIN with that of VEGFR-2 in human melanoma tissues as well as with the extent of HIF-2α localization in the nucleus. They demonstrate a novel mechanism by which EMMPRIN promotes tumor progression through HIF-2α/VEGFR-2 mediated mechanism, with an autocrine role in melanoma cell malignancy. The inhibition of EMMPRIN in cancer may thus simultaneously target both the VEGFR-2/VEGF system and the matrix degrading proteases to block tumor cell growth and invasion.
靶向 CD147 的 siRNA 通过下调糖酵解抑制人恶性黑色素瘤细胞的增殖、侵袭和 VEGF 产生
DOI: 10.1016/j.canlet.2008.07.034
发表时间: 2009-01-08
期刊: CANCER LETTERS
影响因子: 9.7
作者:
Su, Juan;Chen, Xiang;Kanekura, Takuro
通讯作者: Kanekura, Takuro
DOI: 10.1371/journal.pmed.0040186
发表时间: 2007-06
期刊: PLoS medicine
影响因子: 15.8
作者:
Lee TH;Seng S;Sekine M;Hinton C;Fu Y;Avraham HK;Avraham S
通讯作者: Avraham S
DOI: 10.1111/j.0022-202x.2004.23460.x
发表时间: 2004-12-01
影响因子: 6.5
作者:
Graells, J;Vinyals, A;Fabra, A
通讯作者: Fabra, A
DOI: 10.1038/sj.onc.1210114
发表时间: 2007-05-10
期刊: ONCOGENE
影响因子: 8
作者:
Shields, J. D.;Emmett, M. S.;Bates, D. O.
通讯作者: Bates, D. O.
DOI: 10.1128/mcb.23.14.4959-4971.2003
发表时间: 2003-07-01
影响因子: 5.3
作者:
Park, SK;Dadak, AM;Johnson, RS
通讯作者: Johnson, RS